Triple

T195373
Position Surface form Disambiguated ID Type / Status
Subject Biogen E3807 entity
Predicate hasProduct P3585 FINISHED
Object Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
 E25438 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Tecfidera | Statement: [Biogen, hasProduct, Tecfidera]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Tecfidera
Context triple: [Biogen, hasProduct, Tecfidera]
  • A. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • B. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • C. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • D. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • E. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Tecfidera
Triple: [Biogen, hasProduct, Tecfidera]
Generated description
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Tecfidera
Target entity description: Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • A. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • B. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • C. Spinraza
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • D. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • E. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a2548debd48190ae3a06d6e65b53c6 completed Feb. 28, 2026, 2:35 a.m.
NER Named-entity recognition batch_69a25969425081908e178db8ba4631c2 completed Feb. 28, 2026, 2:56 a.m.
NED1 Entity disambiguation (via context triple) batch_69a31c91b22c8190a1d04983ae4fd793 completed Feb. 28, 2026, 4:49 p.m.
NEDg Description generation batch_69a31ea66b8881909748ab11d7a4a50a completed Feb. 28, 2026, 4:58 p.m.
NED2 Entity disambiguation (via description) batch_69a31efbe2d48190b528011dfdf764c1 completed Feb. 28, 2026, 4:59 p.m.
Created at: Feb. 28, 2026, 2:41 a.m.